Indolent primary effusion lymphoma-like lymphoma in the pericardium: A case report and review of the literature

Yamaoka, Osamu; Matsui, Toshiki; Nishiyama, Keizo; Miyamoto, Akashi; Shiota, Hiromi; Kawahara, Chiho; Shikano, Mayumi; Nagao, Masatoshi; Minamiguchi, Hitoshi; Takemura, Shizuki

doi:10.1016/j.jccase.2018.12.013

Cited by 4 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 10 For this reason, and as we and others have suggested elsewhere, CD20 targeting therapy with rituximab in combination with thoracentesis of effusion fluid seems to be an acceptable alternative treatment option in CD20 positive patients who cannot withstand CHOP-like chemotherapy due to increased age or an inadequate performance functional status. 11 , 14 , 18 Our patient was able to successfully complete R-CHOP after initial treatment with rituximab monotherapy and rituximab-cyclophosphamide.…”

Section: Discussionmentioning

confidence: 80%

Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy

Kuhlman

Moustafa

Jiang

et al. 2021

JBM

View full text Add to dashboard Cite

Effusion-based lymphomas (EBL) are usually high-grade B cell non-Hodgkin’s lymphomas which involve effusion fluid in a body cavity, typically presenting as a pleural effusion, without evidence of disease elsewhere. They are most frequently seen in HIV-infected individuals and are biologically driven by human herpesvirus-8 virus (HHV-8). HHV-8 (+) EBL is recognized as primary effusion lymphoma (PEL) under the World Health Organization classification. HHV-8 (-) EBL has been reported in association with Hepatitis C virus (HCV) infection, Epstein-Barr virus (EBV) infection, fluid overload, liver cirrhosis, renal dysfunction, cardiac arrhythmias, myocardial infarction, and heart failure. These cases can be labeled as primary EBL (PEBL). We describe a non-germinal center B cell diffuse large B cell lymphoma (NGCB-DLBCL) presenting as PEBL in an immunocompetent 81-year-old male who had an extensive cardiac history and tested negative for HIV, HHV-8, and EBV. He was treated with thoracentesis and standard anthracycline-based chemoimmunotherapy and has remained in complete remission for over 5 ½ years since his original diagnosis. Our case indicates that NGCB-DLBCL can present as PEBL and is potentially curable with the standard chemoimmunotherapeutic approach.

show abstract

Section: Discussionmentioning

confidence: 80%

Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy

Kuhlman

Moustafa

Jiang

et al. 2021

JBM

View full text Add to dashboard Cite

show abstract

“…18 One case of HHV8-negative EBL in the pericardium was treated with 8 doses of rituximab over a 2 month period, resulting in complete response for >12 months. 19 In another report, two older patients with HHV8-negative EBL, ages 90 and 87, were treated with rituximab alone and demonstrated complete remission. 18 Interestingly, reports of patients being treated with thoracentesis alone have also demonstrated positive responses in older patients with a poor functional status.…”

Section: Discussionmentioning

confidence: 99%

“…Rituximab targeting CD20 has demonstrated significant benefit in selected patients according to multiple reports 18 . One case of HHV8‐negative EBL in the pericardium was treated with 8 doses of rituximab over a 2 month period, resulting in complete response for >12 months 19 . In another report, two older patients with HHV8‐negative EBL, ages 90 and 87, were treated with rituximab alone and demonstrated complete remission 18 .…”

Section: Discussionmentioning

confidence: 99%

Primary age‐related EBV‐associated effusion‐based lymphoma successfully treated with rituximab and thoracentesis

Kuhlman

Moustafa

Tun

et al. 2021

Clinical Case Reports

View full text Add to dashboard Cite

We report a 98-year-old patient with primary age-related EBV-associated effusion-based lymphoma (aEBV-EBL) in the setting of persistent transudative pleural effusion. He was treated with rituximab and thoracentesis achieving complete remission. We suggest that aEBV-EBL is a subtype of EBVpositive HHV8-negative EBL, which is part of the EBVpositive DLBCL-NOS spectrum.Primary human herpesvirus 8-negative effusion-based lymphoma (HHV8-negative EBL) is a distinct category of non-Hodgkin lymphoma which manifests as a serous effusion without a distinct tumor mass. The hallmark of a HHV8-negative EBL diagnosis is negativity for HHV8 infection, thereby distinguishing itself from primary effusion lymphoma (PEL) which requires the presence of HHV8 infection. 1 HHV8-negative EBL has been found in association with hepatitis C virus (HCV) infection, fluid overload, liver cirrhosis, renal dysfunction, cardiac arrhythmias, myocardial infarction, and heart failure. [2][3][4][5] Epstein-Barr virus (EBV) infection has been reported in 13% of HHV8-negative EBL cases. 3 EBV-positive and HHV8-negative EBL have been reported in patients with liver disease, HIV, lymphocytopenia, common variable immunodeficiency, solid organ transplant, and renal disease. 2,[6][7][8][9][10] EBV-positive DLBCL-NOS is a well-defined entity in the World Health Organization (WHO) classification of B-cell lymphomas. EBV-positive and HHV8-negative EBL can be defined as EBV-positive DLBCL-NOS primarily presenting as EBL. Age-related EBV-associated DLBCL, another wellknown entity seen in elderly patients, is also recognized as part of the spectrum of EBV-positive DLBCL-NOS. 11,12 This entity is known to follow an aggressive clinical course when compared against EBV-negative DLBCL. 13,14 Herein, we report an extremely rare case of primary age-related EBV-associated effusion-based lymphoma in a 98-year-old man who achieved complete remission following rituximab monotherapy and thoracentesis. We further discuss

show abstract

Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics

et al. 2022

View full text Add to dashboard Cite

Indolent primary effusion lymphoma-like lymphoma in the pericardium: A case report and review of the literature

Cited by 4 publications

References 20 publications

Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy

Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy

Primary age‐related EBV‐associated effusion‐based lymphoma successfully treated with rituximab and thoracentesis

Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics

Contact Info

Product

Resources

About